Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy

J Clin Oncol. 2007 Dec 10;25(35):5667-9. doi: 10.1200/JCO.2007.14.6134.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Carboplatin / administration & dosage
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / pathology*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm, Residual / pathology
  • Paclitaxel / administration & dosage
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy
  • Pregnancy Complications, Neoplastic / pathology
  • Receptor, ErbB-2 / analysis*
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Receptor, ErbB-2
  • Paclitaxel